Esperion Therapeutics | ESPR - Loan Capital


Esperion Therapeutics reported $457.65M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Cipla INR 2.98B 454.6M Sep/2025
CSL USD 10.42B 273M Dec/2025
Cytokinetics USD 1.12B 957.23M Dec/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Geron USD 119.55M 283K Dec/2025
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Merck USD 39.97B 6B Sep/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 610M 584M Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024